High-Tech Prostate Cancer Treatments: A Cost Analysis
NEW YORK, Feb. 15, 2013 /PRNewswire/ -- Staying ahead of the curve often comes with a price. In the case of prostate cancer, treatment innovations fuel ongoing debate over the cost-benefit analysis of new technologies and modalities. In an institution-based study led by Dr. David Samadi, Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York, Robotic-Assisted Laparoscopic Prostatectomy (RALP) was found to be less than half the cost of radiation.
Focused on localized prostate cancer treatments from 2005 to 2009, researchers compared Mount Sinai hospital expenses for open prostate surgery, robotic surgery, brachytherapy seed radiation, Intensity Modulated Radioactive Therapy (IMRT), and a combination of brachytherapy and IMRT. Among the findings presented by Dr. Samadi at the European Association of Urology 27 th Annual Congress in Paris last February, was a savings of more than $8,000 per RALP procedure over IMRT radiation.
Median cost comparison for prostate cancer treatment options:
- Brachytherapy: $7,560
- Robotic prostate removal surgery: $7,676
- Open prostate removal surgery: $8,991
- Radiation therapy (IMRT): $15,929
- Brachytherapy/IMRT combined for high-risk patients: $22,447
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts